ORIGIN SC offers one of the broadest portfolio of sizes available for an SC balloon, including 1.00 mm, 1.25 mm, 1.50 mm and 1.75 mm balloon diameters to treat very small vessels and complex cases.
The objective of the study is to collect ‘real-world’ safety, efficacy, health economics, and patient-reported quality-of-life data in over 700 patients with PAD treated with SELUTION SLR.
PRESTIGE* is a prospective, single-center, physician-initiated clinical study, run at the Singapore General Hospital (SGH) by Associate Professor Tze Tec Chong and Dr. Tjun Yip Tang.
The PRISTINE registry is a follow up to the encouraging results seen in the PRESTIGE clinical trial (Below The Knee, Chronic Limb Threatening Ischemia) at 6 months.
The SELUTION SLR™ Study involves up to 132 patients across a number of centres in Japan. Its objective is to assess the safety and efficacy of SELUTION SLR for the treatment of lesions of superficial femoral arteries and/or popliteal arteries.
MedAlliance Announces Enrollment of the 1st Patient In Its SELUTION SLR™ 014 DEB Study for the treatment of In-Stent Restenosis
The objectives of this prospective, randomized, single-blind multicenter study are to demonstrate the safety and efficacy o SELUTION SLR™ 014 DEB n the treatment of ISR with either drug-eluting or bare-metal stents. The study will support the submission for FDA approval.
SELUTION SLR Sirolimus Drug Eluting Balloon for Endovascular Applications Receives CE Approval: Award Supported by 2 Year Results from the SELUTION SLR First-in-Human Study Involving 50 Patients
This award was supported by two-year results from the SELUTION SLR First-in-Human study, involving 50 patients enrolled across four German centres.